SEC Form 4 · accession 0001171843-18-001902
Anika Therapeutics, Inc. · ANIK
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Joseph G Darling
Officer — President and CEO; Director · Director
Period of report
Mar 9, 2018
Accepted (ET)
Mar 13, 2018 · 4:05 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000898437
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Mar 9, 2018 | A | 7,478 | $0.00 | A | 21,984 | D | |
| Common StockF2 | Mar 9, 2018 | F | 548 | $53.49 | D | 21,436 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Restricted stock awards vest in four equal annual installments on March 9, 2018, March 9, 2019, March 9, 2020, and March 9, 2021.
- F2Reflects an aggregate of 548 shares of common stock retained by the Issuer to satisfy tax withholding obligations.